The DOI matches its Crossref record; the references it cites are not checked yet; 18 of the 85 sources its claims cite were checked for support.
Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations
Open accessAbstract
BACKGROUND: Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a systematic review of these studies to highlight the effect that important methodological limitations have on such analyses and to consider approaches to the conduct, reporting and interpretation of future studies. METHODS: A review of MEDLINE and EMBASE identified case-control, cohort and sibling studies assessing the risk of ASD and ADHD with antidepressant use during pregnancy. Approaches to confounding adjustment were described. Crude and adjusted effect estimates for comparisons between antidepressant exposure during pregnancy vs. all unexposed women were first meta-analysed using a generic inverse variance method of analysis, followed by effect estimates for alternative pre-selected comparison groups. RESULTS: A total of 15 studies measuring ASD as an outcome (involving 3,585,686 children and 40,585 cases) and seven studies measuring ADHD as an outcome (involving 2,765,723 patients and 52,313 cases) were identified. Variation in confounding adjustment existed between studies. Updated effect estimates for the association between maternal antidepressant exposure during pregnancy vs. all unexposed women remained statistically significant for ASD (adjusted random-effects risk ratio [RaRR] 1.53, 95% confidence interval [CI] 1.31-1.78). Similar significant associations were observed using pre-pregnancy maternal antidepressant exposure (RaRR 1.48, 95% CI 1.29-1.71) and paternal antidepressant exposure during pregnancy (1.29, 95% CI 1.08-1.53), but analyses restricted to using women with a history of affective disorder (1.18, 95% CI 0.91-1.52) and sibling studies (0.96, 95% CI 0.65-1.42) were not statistically significant. Corresponding associations for risk of ADHD with exposure were: RaRR 1.38, 95% CI 1.13-1.69 (during pregnancy), RaRR 1.38, 95% CI 1.14-1.69 (during pre-pregnancy), RaRR 1.71, 95% CI 1.31-2.23 (paternal exposure), RaRR 0.98, 95% CI 0.77-1.24 (women with a history of affective disorder) and RaRR 0.88, 95% CI 0.70-1.11 (sibling studies). CONCLUSIONS: Existing observational studies measuring the risk of ASD and ADHD with antidepressant exposure are heterogeneous in their design. Classical comparisons between exposed and unexposed women during pregnancy are at high risk of residual confounding. Alternative comparisons and sibling designs may aid the interpretation of causality and their utility requires further evaluation, including understanding potential limitations of undertaking meta-analyses with such data.
Overview
CoChat Summary
## TL;DR
This systematic review of 15 ASD studies and 7 ADHD studies found that the classic comparison of antidepressant-exposed vs all unexposed pregnancies showed statistically significant associations, but alternative comparisons and sibling designs generally did not. The authors conclude that residual confounding, especially confounding by indication and depression severity, likely explains much of the association.
## Key findings
- For ASD, 15 studies included 3,585,686 children and 40,585 cases; the pooled adjusted random-effects risk ratio for maternal antidepressant exposure during pregnancy vs all unexposed women was 1.53 (95% CI 1.31–1.78).
- For ADHD, 7 studies included 2,765,723 patients and 52,313 cases; the pooled adjusted random-effects risk ratio for maternal antidepressant exposure during pregnancy vs all unexposed women was 1.38 (95% CI 1.13–1.69).
- Alternative comparisons were not statistically significant in several cases: for ASD, women with a history of affective disorder had RaRR 1.18 (95% CI 0.91–1.52) and sibling studies RaRR 0.96 (95% CI 0.65–1.42); for ADHD, women with a history of affective disorder had RaRR 0.98 (95% CI 0.77–1.24) and sibling studies RaRR 0.88 (95% CI 0.70–1.11).
- Paternal antidepressant exposure during pregnancy was also associated with increased risk in pooled analyses: ASD RaRR 1.29 (95% CI 1.08–1.53) and ADHD RaRR 1.71 (95% CI 1.31–2.23).
## Methods
- Systematic review of observational studies published on or before May 2017, searching MEDLINE and EMBASE; eligible designs were case–control, cohort, and sibling studies.
- Included studies assessed ASD and ADHD outcomes after antidepressant exposure during pregnancy; data were extracted on study design, comparators, sample size, confounder adjustment, and crude/adjusted effect estimates.
- Crude and adjusted effect estimates were pooled using a generic inverse variance method with random-effects models; fixed-effect models, leave-one-out analyses, and sensitivity analyses by comparator group and study design were also performed.
## Limitations
- The paper states that observational studies are limited by unmeasured confounding, especially confounding by indication and severity of depression, and by heterogeneity in confounding adjustment across studies.
- It also states that outcome coding in administrative databases may cause misclassification, and that pre-pregnancy exposure may not have been cleanly separated from continued pregnancy exposure in all studies.
- Evident from the text: some alternative comparator groups had few studies/effect estimates, limiting inference; the authors also note they did not contact study authors and their search was limited to the databases used.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
3 Valid · 1 Not valid · 23 Not checked · 88 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“there was a total of 15 observational studies measuring ASD as an outcome [16–19, 25–35].”
§ Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations > Results > Autism spectrum disorder
What the sources say
- Not checked yetcites [16] Boukhris T, Sheehy O, Mottron L, Bérard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2015;14:1–8.
- Supportedcites [17] Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2014; https://doi.org/10.1038/mp.2014.90 . source
This citation identifies the paper as one of the observational studies measuring ASD as an outcome. The Methods describe ASD cases matched to healthy controls, and the Results report analyses of antidepressant exposure and ASD risk. The paper does not need to establish the citing document’s total of 15 studies on its own. (LLM, conf=0.91)
- Supportedcites [18] Castro VM, Kong SW, Clements CC, Brady R, Kaimal AJ, Doyle AE, et al. Absence of evidence for increase in risk for autism or attention deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Transl Psychiatry. 2016;6:e708 [published online 5 January 2016]. source
The Cohort definition and Analysis sections describe an observational study comparing children with ASD against controls and modeling associations with maternal antidepressant exposure. The Results section reports ASD as an outcome. This supports citing the paper as one of the observational studies in the group; the paper does not itself establish the total of 15. (LLM, conf=0.90)
- Not checked yetcites [19] El Marroun H, White T, Verhulst FC, Tiemeier H. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(10):973–92. source
- Not checked yetcites [25] Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA. 2017;317:1544–52. source
- Not checked yetcites [26] Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12. source
- Not checked yetcites [27] Eriksson MA, Westerlund J, Anderlid BM, Gillberg C, Fernell E. First-degree relatives of young children with autism spectrum disorders: some gender aspects. Res Dev Disabil. 2012;33(5):1642–8. source
- Not checked yetcites [28] Gidaya NB, Lee BK, Burstyn I, Yudell M, Mortensen EL, Newschaffer CJ. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J Autism Dev Disord. 2014; https://doi.org/10.1007/s10803-014-2128-4 . source
- Supportedcites [29] Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241–8. source
The Discussion identifies this paper as a population-based case-control study of prenatal SSRI use and ASD risk, and the Methods report 492 children with ASD. It therefore supports its citation as one of the observational studies measuring ASD as an outcome; the citation group, not this paper alone, supplies the total of 15. (LLM, conf=0.88)
- Not checked yetcites [30] Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406–15. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“a total of seven observational studies measuring ADHD as an outcome [17, 18, 31, 34, 36–38] were identified”
§ Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations > Results > Attention deficit hyperactivity disorder
What the sources say
- Supportedcites [17] Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2014; https://doi.org/10.1038/mp.2014.90 . source
This citation identifies one of the observational studies counted by the citing authors, rather than attributing the count of seven to this paper. The Methods (Overview and data set generation) describe children with ADHD and matched controls, and the Methods (Analysis) describe models assessing ADHD as an outcome. (LLM, conf=0.91)
- Supportedcites [18] Castro VM, Kong SW, Clements CC, Brady R, Kaimal AJ, Doyle AE, et al. Absence of evidence for increase in risk for autism or attention deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Transl Psychiatry. 2016;6:e708 [published online 5 January 2016]. source
The Cohort definition describes an ADHD cohort, and the Analysis section describes observational comparisons of ADHD cases with controls. This paper is therefore one of the observational studies with ADHD as an outcome identified by the citing sentence; the total of seven refers to the cited set, not a count this paper must establish. (LLM, conf=0.91)
- Supportedcites [31] Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study. J Am Acad Child Adolesc Psychiatry. 2016;55:359–66. source
The Abstract > Method describes this paper as a Finnish national register-based cohort study and states that it investigated offspring ADHD diagnoses. The citation identifies one observational study measuring ADHD as an outcome; the claim does not attribute the count of seven to this paper alone. (LLM, conf=0.92)
- Supportedcites [34] Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317:1553–62. source
The citation identifies this paper as one of seven observational studies measuring ADHD as an outcome; it does not attribute the count of seven to this paper. The Methods (Measures and Analyses) identify ADHD as a neurodevelopmental outcome and describe observational comparisons of antidepressant exposure and offspring outcomes. (LLM, conf=0.91)
- Not checked yetcites [36] Figueroa R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr. 2010;31(8):641–8. source
- Supportedcites [37] Laugesen K, Olsen MS, Telen Andersen AB, Sorensen HT. In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study. BMJ Open. 2013;3(9):e003507. source
This citation identifies one of the observational studies counted by the citing authors; the total of seven is their own tally, not a finding attributed to this paper. The Methods (Statistical analyses) describe cohort comparisons, and the Results report children who developed ADHD. (LLM, conf=0.93)
- Supportedcites [38] Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017;357:j2350. source
The citation identifies this paper as one of the observational studies measuring ADHD as an outcome, rather than attributing the citing authors’ total count of seven to it. The Methods section (‘Outcome definition’) identifies ADHD diagnosis or ADHD-drug prescription as the study outcomes in liveborn children. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 15 observational studies measuring ASD as the outcome, all reported adjusted effect estimates for the comparison between maternal antidepressant exposure during pregnancy vs. all unexposed women (nine of which reported effect estimates by trimester).”
§ Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations > Results > Autism spectrum disorder
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effect estimate for the risk of ASD associated with maternal antidepressant exposure during pregnancy reported by three within-family sibling studies did not suggest an increase in risk (RaRR 0.96, 95% CI 0.65–1.42).”
§ Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations > Results > Attention deficit hyperactivity disorder
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RaRR 0.88, 95% CI 0.70–1.11 (sibling studies)”
§ Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims
Create a free account to see all 115 claims and to verify the 67 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The body of evidence produced from these two methods generally support no association between prenatal SSRI exposure and ASD (18).”
From Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders (2021) · cites this paper as [18]
In the citing paper
“In evaluating these methods, a recent systematic review of the literature determined that study designs using SSRI-unexposed mothers with psychiatric conditions (as was done in the present study) and/or siblings as comparators afford the most rigorous approaches for circumventing issues of residual confounding by psychiatric indication (18).”
From Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders (2021) · cites this paper as [18]
In the citing paper
“Among the 120 associations, 3 (2.5%) were supported by convincing evidence, namely, the association between SSRI use and increased risk of suicide attempt or completion in children and adolescents 80 as well as the association between exposure to any antidepressant before pregnancy and SSRIs during pregnancy and autism spectrum disorder 51,52 (Table 2).”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [51]
In the citing paper
“We reviewed 45 meta-analyses of observational studies and found that only a few of the 74 statistically significant associations between antidepressants and adverse health outcomes were supported by convincing evidence in the main and sensitivity analyses, namely, the association between antidepressant use and increased suicide attempt or completion in individuals younger than 19 years (SSRI studi”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as [51]
In the citing paper
“RR: 1.87 | (1.52 to 2.30)”
From Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review (2019) · cites this paper as Morales et al, 51 2018
Citations
The citation lists are queued
They are fetched later and appear here then.
References 49 · Cited by 118
Research works printed but not linked: 1
- CIOMS Working Group X. Evidence synthesis and meta-analysis, Chapter 3. 2016.
Metadata
- Authors
- Morales, D. R., Slattery, J., Evans, S., & Kurz, X.
- Affiliations
- European Medicines Agency (NL)
- University of London (GB)
- Corresponding author
- Morales, Daniel R.
- Venue
- BMC Medicine
- Published
- 2018-01-15
- Volume
- 16
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC5767968
- OpenAlex
- W2783908905
- Cited by
- 118
- References
- 49
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 11 · 2023: 14 · 2022: 18 · 2021: 16 · 2020: 21 · 2019: 20 · 2018: 5
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (acceptedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- autism spectrum disorder, attention deficit hyperactivity disorder, maternal antidepressant use, confounding adjustment, mood disorders, prenatal drug exposure, reporting quality, sibling studies, confounding by indication
- MeSH terms
- Autism Spectrum Disorder, Adult, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Risk Factors, Cohort Studies, Epidemiologic Research Design, Case-Control Studies, Mood Disorders, Young Adult, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. https://app.cochat.ai/papers/10.1186/s12916-017-0993-3
- The paper
- Morales, D. R., Slattery, J., Evans, S., & Kurz, X. (2018). Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Medicine. https://doi.org/10.1186/s12916-017-0993-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.